Accolade

HealthtechUSA

New to Unitard

🤝 Acquired

Peak $3.5 BillionToday

~-82%

from peak

🦄
Became a unicorn
2020
📈
Peak valuation
$3.5 Billion ’21
💔
Became a Unitard
~2022
💸
Last valuation
~$630M

Current status

Acquired by Transcarent for $621M (2025), delisted

The rise & fall

7 moments · 2007–2025

The key moments, with employee sentiment along the way.

2007

Founded as employers' front door to healthcare

Human advocates plus software to help big companies' employees find care and decode their benefits.

Wikipedia

Jul 2020

IPO makes it a unicorn

Lists on Nasdaq as ACCD in the middle of the pandemic's virtual-care surge.

CNBC

2021

The peak: ~$3.5B market cap$3.5B

The digital-health wave crests in early 2021, and Accolade crests with it.

Macrotrends

2022–24

The digital-health hangover

Growth slows, the sector's pandemic premium evaporates, and the stock grinds down toward single digits.

STAT News

2022

Slips out of the club

Market cap falls below $1B as the digital-health selloff deepens.

Macrotrends

2022–24

From the inside · Glassdoor reviews, 2022–24

Glassdoor reviews from the slide described year-after-year layoff rounds — some cutting hundreds of roles at a time — frequent reorganizations and senior-leadership churn, repeated return-to-office reversals, and frontline work shifting to lower-cost hubs such as Prague.

Jan 2025

Acquired by Transcarent for $621M$621M

Glen Tullman's Transcarent agrees to take it private at $7.03 a share — less than a fifth of the peak. The deal closes in April 2025 and ACCD delists.

CNBC

💬 entries paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗; dated facts carry their source.

How it happened

Accolade paired human advocates with technology to help large employers' staff find care, understand benefits and get expert medical opinions. It went public in 2020 and rode the pandemic-era digital-health wave to a roughly $3.5B market value in early 2021.

As growth slowed and the sector deflated its shares collapsed, and in early 2025 rival Transcarent took Accolade private for $621M — about $7.03 a share — delisting it from Nasdaq.

Source: STAT News / CNBC / Healthcare Dive (health-benefits navigation and advocacy platform backed by Andreessen Horowitz, Carrick Capital and McKesson Ventures; IPO'd in 2020 and peaked near a $3.5B market cap in early 2021, then slid as growth slowed; Glen Tullman's Transcarent — funded by General Catalyst and 62 Ventures — agreed in January 2025 to take it private for $621M, or $7.03 a share, completing the deal in April 2025)

Founders & leadership

Rajeev Singh
CEO from 2015 (co-founded Concur, not Accolade)
Now Chief Executive Officer at SmartsheetLinkedIn ↗
Tom Spann
co-founder & founding CEO
Now CEO at BrightsideLinkedIn ↗
J. Michael Cline
co-founder (Accretive LLC)
No public profile matched